Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Other Accumulated Expenses: 2019-2024

Historic Other Accumulated Expenses for Legend Biotech (LEGN) over the last 6 years, with Dec 2024 value amounting to $166.2 million.

  • Legend Biotech's Other Accumulated Expenses fell 10.72% to $147.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $147.2 million, marking a year-over-year decrease of 10.72%. This contributed to the annual value of $166.2 million for FY2024, which is 35.87% up from last year.
  • Latest data reveals that Legend Biotech reported Other Accumulated Expenses of $166.2 million as of FY2024, which was up 35.87% from $122.3 million recorded in FY2023.
  • In the past 5 years, Legend Biotech's Other Accumulated Expenses registered a high of $184.1 million during FY2022, and its lowest value of $99.2 million during FY2020.
  • Its 3-year average for Other Accumulated Expenses is $157.5 million, with a median of $166.2 million in 2024.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first spiked by 139,861.05% in 2020, then plummeted by 33.57% in 2023.
  • Legend Biotech's Other Accumulated Expenses (Yearly) stood at $99.2 million in 2020, then increased by 24.59% to $123.6 million in 2021, then soared by 49.01% to $184.1 million in 2022, then plummeted by 33.57% to $122.3 million in 2023, then surged by 35.87% to $166.2 million in 2024.